Clinical Research Directory

Inclusion Criteria: * Volunteer and sign the informed consent in person. * Aged 18-65 * Pathological diagnosis of non-keratinizing NPC (differentiated or undifferentiated, as WHO II, III type). * Clinical stage of III-IVA（8thAJCC/UICC staging system） * Complete induction chemotherapy and concurrent chemoradiotherapy. * With ECOG score 0-1. * Female subjects: surgical sterilization or postmenopausal patients, or agree to use a medical approved contraceptive measure such as Intrauterine device (IUD), contraceptives or condoms during the study period. * HGB \<130g/L(male)，HGB\<120g/L(female). * Serum ferritin≤800ug/L。 * Liver function: ALT, AST \< 2.5 times the upper limit of normal (ULN), total bilirubin \< 2.0 × ULN; * Renal function: serum creatinine \<1.5×ULN. Exclusion Criteria: * Recurrence or distant metastasis nasopharyngeal carcinoma. * Keratinizing squamous cell carcinoma (WHO type I). * Pregnant or breastfeeding women, who are in their childbearing years and have not used effective contraception. * Previous or concurrently with other malignancies, exclude cured skin basal cell carcinoma and cervical carcinoma in situ. * Patients with severely diminished functions of the heart, liver, lung, kidney and bone marrow; * Serious, unmanaged medical conditions and infections. * Those with other therapeutic contraindications. * Use of other investigational medications or clinical studies concurrently. * Refused or incapacity to sign the informed consent to participate in the study. * People having mental or personality disorders, disability, or limited civil capacity. * Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study. * HGB\>130g/L(male)，HGB \>120g/L(female). * Received transfusion therapy before. * Receipt of oral or IV iron supplements or ESAs up to 4 weeks before inclusion * Ferritin \> 800 ng/ml * Ongoing bleeding.